HEFT Repository

Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment.

McGill, Janet B and Barnett, Anthony H and Lewin, Andrew J and Patel, Sanjay and Neubacher, Dietmar and von Eynatten, Maximilian and Woerle, Hans-Juergen (2014) Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment. Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 11 (1). pp. 34-40. ISSN 1752-8984. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk using their Athens ID

Full text not available from this repository.
Official URL: http://dvr.sagepub.com/content/11/1/34.long [Full ...

Abstract

Glucose-lowering treatment options are limited for uncontrolled type 2 diabetes mellitus (T2DM) patients with advanced stages of renal impairment (RI). This retrospective analysis evaluated glycaemic efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor linagliptin added to sulphonylurea. Three randomized phase 3 studies (n = 619) including T2DM subjects with moderate or severe RI [estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m(2)] were analysed; only sulphonylurea-treated subjects who received additional linagliptin (n = 58) or placebo (n = 33) were evaluated. Linagliptin provided meaningful placebo-adjusted HbA1c reductions of -0.68% (95% confidence interval: -1.19, -0.17), -1.08% (-2.02, -0.14) and -0.62% (-1.25, 0.01) after 24, 18 and 12 weeks, respectively. There was a similar incidence of overall adverse events (linagliptin: 79.3%, placebo: 75.8%) and hypoglycaemia (linagliptin: 37.9%, placebo: 39.4%). Severe hypoglycaemia was more common with placebo (linagliptin: 1.7%, placebo: 6.1%). These data suggest that linagliptin is a safe and effective glucose-lowering treatment in T2DM patients with moderate-to-severe RI for whom sulphonylurea treatment is no longer sufficient.

Item Type: Article
Additional Information: This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk using their Athens ID
Subjects: WJ Urogenital system. Urology
WK Endocrine system. Endocrinology
Divisions: Ambulatory Care > Diabetes
Related URLs:
Depositing User: Sophie Rollason
Date Deposited: 19 Jun 2014 09:42
Last Modified: 19 Jun 2014 09:42
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/282

Actions (login required)

View Item View Item